{"id":232775,"date":"2026-03-07T22:17:33","date_gmt":"2026-03-08T04:17:33","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/03\/triglycerides-induce-endoplasmic-reticulum-lipid-bilayer-stress-to-activate-perk-and-enhance-antifungal-immunity"},"modified":"2026-03-07T22:17:33","modified_gmt":"2026-03-08T04:17:33","slug":"triglycerides-induce-endoplasmic-reticulum-lipid-bilayer-stress-to-activate-perk-and-enhance-antifungal-immunity","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/03\/triglycerides-induce-endoplasmic-reticulum-lipid-bilayer-stress-to-activate-perk-and-enhance-antifungal-immunity","title":{"rendered":"Triglycerides induce endoplasmic reticulum lipid bilayer stress to activate PERK and enhance antifungal immunity"},"content":{"rendered":"<p style=\"padding-right: 20px\"><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/triglycerides-induce-endoplasmic-reticulum-lipid-bilayer-stress-to-activate-perk-and-enhance-antifungal-immunity2.jpg\"><\/a><\/p>\n<p>Fungal infections present persistent therapeutic challenges in immunocompromised populations, including individuals with acquired immunodeficiency syndrome (AIDS), organ transplant recipients receiving immunosuppressive therapy, long-term hospitalized patients, patients with cancer, and those receiving immunomodulatory agents.<a id=\"crosref0115\" href=\"http:\/\/dlvr.it\/TRLr5b#bib1\" data-xml-rid=\"bib1\"><sup>1<\/sup><\/a> These infections demonstrate remarkable recalcitrance to conventional therapies, compounded by fungal adaptability to environmental stresses, the emergence of drug-resistant strains, and the limited availability of clinically available antifungal agents.<a id=\"crosref0120\" href=\"http:\/\/dlvr.it\/TRLr5b#bib2\" data-xml-rid=\"bib2\"><sup>2<\/sup><\/a> Systemic fungemia has alarmingly high mortality rates, accounting for approximately 1.5 million annual deaths worldwide, a burden comparable to AIDS-and tuberculosis-related mortality.<a id=\"crosref0125\" href=\"http:\/\/dlvr.it\/TRLr5b#bib3\" data-xml-rid=\"bib3\"><sup>3<\/sup><\/a> <i><i>Candida<\/i> albicans<\/i> is the most frequently isolated fungal pathogen in clinical settings. Despite therapeutic advances, invasive candidiasis persists with mortality rates exceeding 40%,<a id=\"crosref0130\" href=\"http:\/\/dlvr.it\/TRLr5b#bib4\" data-xml-rid=\"bib4\"><sup>4<\/sup><\/a> underscoring the urgent need to elucidate host immune mechanisms against fungal pathogens.<\/p>\n<p>When innate immune cells, such as macrophages, dendritic cells, and neutrophils, encounter fungi, the pattern recognition receptors (PRRs) on their surface recognize evolutionarily conserved fungal cell wall components, including \u03b2-glucan and \u03b1-mannan (classified as pathogen-associated molecular patterns), thereby initiating downstream signaling cascades and immune responses. The primary PRRs involved in fungal recognition are C-type lectin receptors (CLRs) and Toll-like receptors. The CLR family comprises Dectin-1 (specific for \u03b2-glucan), Dectin-2\/3 (mannan sensors), Mincle, dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin, and CD23.<sup>5<\/sup> Upon ligand binding, CLRs initiate the phosphorylation of the immunoreceptor tyrosine-based activation motif within the Dectin-1 cytoplasmic tail and the recruitment of the Fc receptor \u03b3-chain to Dectin-2 or Mincle, which serves as a docking site for spleen tyrosine kinase (SYK).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fungal infections present persistent therapeutic challenges in immunocompromised populations, including individuals with acquired immunodeficiency syndrome (AIDS), organ transplant recipients receiving immunosuppressive therapy, long-term hospitalized patients, patients with cancer, and those receiving immunomodulatory agents.1 These infections demonstrate remarkable recalcitrance to conventional therapies, compounded by fungal adaptability to environmental stresses, the emergence of drug-resistant strains, and the [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,1694],"tags":[],"class_list":["post-232775","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-electronics"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/232775","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=232775"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/232775\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=232775"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=232775"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=232775"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}